Mechanisms and treatment of cancer cachexia

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue SUPPL1, 2013, Pages

  Argiles J M ^a   Lopez Soriano F J ^a   Busquets, S ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Anorexia; Cancer; Drugs; Nutraceuticals; Wasting

Indexed keywords

ANAMORELIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CYTOKINE; ENOBOSARM; ETANERCEPT; FORMOTEROL; GHRELIN; GLPG 0492; INFLIXIMAB; MACIMORELIN; MEDROXYPROGESTERONE; MEGESTROL ACETATE; MELANOCORTIN RECEPTOR; MYOSTATIN; OHR 118; OMEGA 3 FATTY ACID; PH 284; PS 178990; SEROTONIN; SEX HORMONE; SUN 11031; THALIDOMIDE; UNCLASSIFIED DRUG;

ANOREXIA; BODY COMPOSITION; BODY WEIGHT; CACHEXIA; COMPUTER ASSISTED TOMOGRAPHY; DUAL ENERGY X RAY ABSORPTIOMETRY; FOOD INTAKE; HUMAN; LEAN BODY WEIGHT; METABOLIC REGULATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL PERFORMANCE; PROTEIN METABOLISM; PROTEIN SYNTHESIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANOREXIA; CANCER; DRUGS; NUTRACEUTICALS; WASTING;

ANIMALS; ANOREXIA; BODY WEIGHT; CACHEXIA; DIETARY SUPPLEMENTS; HUMANS; NEOPLASMS;

EID: 84890865350     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2012.04.011     Document Type: Review

References (50)

1. Evans W.J., Morley J.E., Argiles J., Bales C., Baracos V., Guttridge D., et al. Cachexia: a new definition. Clin Nutr 2008, 27:793-799.
2. Warren S. The immediate cause of death in cancer. Am J Med Sci 1932, 184:610-613.
3. Argiles J.M., Lopez-Soriano F.J., Busquets S. Mechanisms to explain wasting of muscle and fat in cancer cachexia. Curr Opin Support Palliat Care 2007, 1:293-298.
4. Zeisel S.H. Regulation of "nutraceuticals". Science 1999, 285:1853-1855.
5. Ramos E.J., Middleton F.A., Laviano A., Sato T., Romanova I., Das U.N., et al. Effects of omega-3 fatty acid supplementation on tumor-bearing rats. J Am Coll Surg 2004, 199:716-723.
6. Olivan M., Busquets S., Figueras M., Fontes de Oliveira C., Toledo M., Sette A., et al. Nutraceutical inhibition of muscle proteolysis: a role of diallyl sulphide in the treatment of muscle wasting. Clin Nutr 2011, 30:33-37.
7. Read J.A., Beale P.J., Volker D.H., Smith N., Childs A., Clarke S.J. Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. Support Care Cancer 2007, 15:301-307.
8. Ryan A.M., Reynolds J.V., Healy L., Byrne M., Moore J., Brannelly N., et al. Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial. Ann Surg 2009, 249:355-363.
9. Argiles J.M., Lopez-Soriano F.J., Busquets S. Novel approaches to the treatment of cachexia. Drug Discov Today 2008, 13:73-78.
10. De Wys W. Working conference on anorexia and cachexia of neoplastic disease. Cancer Res 1970, 30:2816-2818.
11. Loprinzi C.L., Michalak J.C., Schaid D.J., Mailliard J.A., Athmann L.M., Goldberg R.M., et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993, 11:762-767.
12. Bruera E., Macmillan K., Kuehn N., Hanson J., MacDonald R.N. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990, 66:1279-1282.
13. Neri B., Garosi V.L., Intini C. Effect of medroxyprogesterone acetate on the quality of life of the oncologic patient: a multicentric cooperative study. Anticancer Drugs 1997, 8:459-465.
14. McCarthy H.D., Crowder R.E., Dryden S., Williams G. Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur J Pharmacol 1994, 265:99-102.
15. Strang P. The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients (review). Anticancer Res 1997, 17:657-662.
16. Mantovani G., Maccio A., Esu S., Lai P., Santona M.C., Massa E., et al. Medroxyprogesterone acetate reduces the invitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer 1997, 33:602-607.
17. Tomiska M., Tomiskova M., Salajka F., Adam Z., Vorlicek J. Palliative treatment of cancer anorexia with oral suspension of megestrol acetate. Neoplasma 2003, 50:227-233.
18. Busquets S., Serpe R., Sirisi S., Toledo M., Coutinho J., Martínez R., et al. Megestrol acetate: its impact on muscle protein metabolism supports its use in cancer cachexia. Clin Nutr 2010, 29:733-737.
19. Nagaya N., Kojima M., Kangawa K. Ghrelin, a novel growth hormone-releasing peptide, in the treatment of cardiopulmonary-associated cachexia. Intern Med 2006, 45:127-134.
20. Garcia J.M., Polvino W.J. Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 2007, 12:594-600.
21. Scarlett J.M., Marks D.L. The use of melanocortin antagonists in cachexia of chronic disease. Expert Opin Investig Drugs 2005, 14:1233-1239.
22. DeBoer M.D., Marks D.L. Therapy insight: use of melanocortin antagonists in the treatment of cachexia in chronic disease. Nat Clin Pract Endocrinol Metab 2006, 2:459-466.
23. Evans R.D., Argiles J.M., Williamson D.H. Metabolic effects of tumour necrosis factor-alpha (cachectin) and interleukin-1. Clin Sci (Lond) 1989, 77:357-364.
24. Yamamoto N., Kawamura I., Nishigaki F., Tsujimoto S., Naoe Y., Inami M., et al. Effect of FR143430, a novel cytokine suppressive agent, on adenocarcinoma colon26-induced cachexia in mice. Anticancer Res 1998, 18:139-144.
25. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991, 173:699-703.
26. Sampaio E.P., Kaplan G., Miranda A., Nery J.A., Miguel C.P., Viana S.M., et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993, 168:408-414.
27. Gordon J.N., Trebble T.M., Ellis R.D., Duncan H.D., Johns T., Goggin P.M. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005, 54:540-545.
28. Anker S.D., Coats A.J. How to recover from renaissance? The significance of the results of recover, renaissance, renewal and attach. Int J Cardiol 2002, 86:123-130.
29. Monk J.P., Phillips G., Waite R., Kuhn J., Schaaf L.J., Otterson G.A., et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 2006, 24:1852-1859.
30. Wiedenmann B., Malfertheiner P., Friess H., Ritch P., Arseneau J., Mantovani G., et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 2008, 6:18-25.
31. Quinn L.S., Haugk K.L., Grabstein K.H. Interleukin-15: a novel anabolic cytokine for skeletal muscle. Endocrinology 1995, 136:3669-3672.
32. Carbo N., Lopez-Soriano J., Costelli P., Alvarez B., Busquets S., Baccino F.M., et al. Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. Biochim Biophys Acta 2001, 1526:17-24.
33. Figueras M., Busquets S., Carbo N., Barreiro E., Almendro V., Argiles J.M., et al. Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Lett 2004, 569:201-206.
34. Busquets S., Figueras M.T., Meijsing S., Carbo N., Quinn L.S., Almendro V., et al. Interleukin-15 decreases proteolysis in skeletal muscle: a direct effect. Int J Mol Med 2005, 16:471-476.
35. Anti M., Marra G., Armelao F., Bartoli G.M., Ficarelli R., Percesepe A., et al. Effect of omega-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer. Gastroenterology 1992, 103:883-891.
36. Rose D.P., Connolly J.M. Effects of dietary omega-3 fatty acids on human breast cancer growth and metastases in nude mice. J Natl Cancer Inst 1993, 85:1743-1747.
37. Tisdale M.J. Mechanism of lipid mobilization associated with cancer cachexia: interaction between the polyunsaturated fatty acid, eicosapentaenoic acid, and inhibitory guanine nucleotide-regulatory protein. Prostaglandins Leukot Essent Fatty Acids 1993, 48:105-109.
38. Fearon K.C., Von Meyenfeldt M.F., Moses A.G., Van Geenen R., Roy A., Gouma D.J., et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003, 52:1479-1486.
39. Fearon K.C., Barber M.D., Moses A.G., Ahmedzai S.H., Taylor G.S., Tisdale M.J., et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 2006, 24:3401-3407.
40. Dewey A., Baughan C., Dean T., Higgins B., Johnson I. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev 2007, CD004597.
41. Mehra M.R., Lavie C.J., Ventura H.O., Milani R.V. Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure. J Heart Lung Transplant 2006, 25:834-838.
42. Busquets S., Figueras M.T., Fuster G., Almendro V., Moore-Carrasco R., Ametller E., et al. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res 2004, 64:6725-6731.
43. Sears M.R., Lötvall J. Past, present and future-beta2-adrenoceptor agonists in asthma management. Respir Med 2005, 99:152-170.
44. Ryall J.G., Schertzer J.D., Murphy K.T., Allen A.M., Lynch G.S. Chronic beta2-adrenoceptor stimulation impairs cardiac relaxation via reduced SR Ca2+-ATPase protein and activity. Am J Physiol Heart Circ Physiol 2008, 294:H2587-H2595.
45. Léger B., Koopman R., Walrand S., Gehrig S.M., Murphy K.T., Lynch G.S. Chronic formoterol administration reduces cardiac mitochondrial protein synthesis and oxidative capacity in mice. Int J Cardiol 2011, 146:270-272.
46. Storer T.W., Woodhouse L.J., Sattler F., Singh A.B., Schroeder E.T., Beck K., et al. A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment. J Clin Endocrinol Metab 2005, 90:4474-4482.
47. Zilbermint M.F., Dobs A.S. Nonsteroidal selective androgen receptor modulator ostarine in cancer cachexia. Future Oncol 2009, 5:1211-1220.
48. Bhasin S., Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care 2009, 12:232-240.
49. Tsuchida K. Targeting myostatin for therapies against muscle-wasting disorders. Curr Opin Drug Discov Devel 2008, 11:487-494.
50. Salehian B., Mahabadi V., Bilas J., Taylor W.E., Ma K. The effect of glutamine on prevention of glucocorticoid-induced skeletal muscle atrophy is associated with myostatin suppression. Metabolism 2006, 55:1239-1247.